A new case report describes a child with Takenouchi-Kosaki syndrome, a rare genetic condition, who received off-label treatment with recombinant human growth hormone. The child was followed for six months. The report says the treatment led to favorable catch-up growth. The child also had other features of the syndrome, including short stature, a distinctive facial appearance, low platelet count, hearing loss, low white blood cell count, and immune problems. No side effects or safety concerns were reported in this case. However, this is only one patient, so the results cannot be generalized. There was no comparison group, and the evidence is considered preliminary. The report provides early information that may help doctors and families, but it does not prove that growth hormone works for this condition. Larger studies are needed before any conclusions can be made. Families should talk with their doctor about any treatment decisions.
Off-label growth hormone yields catch-up growth in Takenouchi-Kosaki syndrome caseGrowth Hormone Shows Early Promise in Rare Genetic Syndrome
AI-generated summary of the cited source, checked by automated accuracy review. How we work
This is a single case report of a pediatric patient with Takenouchi-Kosaki syndrome (TKS) associated with a CDC42 p.Arg68Gln variant. The patient presented with short stature, macrothrombocytopenia, sensorineural hearing loss, leukopenia, hypogammaglobulinemia, and humoral immunodeficiency. Off-label recombinant human growth hormone (rhGH) was administered.
The primary outcome was catch-up growth. Over a 6-month follow-up, favorable catch-up growth was achieved. No effect size, absolute numbers, p-values, or confidence intervals were reported. Safety data, including adverse events, serious adverse events, discontinuations, and tolerability, were not reported.
The authors state that this provides preliminary evidence for rhGH intervention and reference information for clinical management and genetic counseling of patients with TKS. However, the evidence is limited by the small sample size (single case report) and the preliminary nature of the findings. No funding or conflicts of interest were reported.
Given the uncontrolled, single-case design, no causal inference can be drawn. Clinicians should interpret this as hypothesis-generating only. The role of rhGH in TKS remains unproven and requires further study.
How this fits prior evidence
This case report extends prior coverage of growth hormone therapies for short stature, such as once-weekly long-acting growth hormone showing comparable efficacy to daily growth hormone in children with short stature, and a novel PTHLH variant associated with brachydactyly type E and short stature. Unlike those reports, this is a single case of TKS, a distinct syndromic condition. It also touches on sensorineural hearing loss, a feature of TKS, which prior coverage addressed through systematic reviews of ferroptosis mechanisms and CAEP correlates, and a trial of hearing aids versus PSAPs. The present report offers no comparative efficacy data.
Common questions
What is Takenouchi-Kosaki syndrome?
Takenouchi-Kosaki syndrome is a rare genetic condition. It can cause short stature, a distinctive facial appearance, low platelet count, hearing loss, low white blood cell count, and immune problems. The report describes one child with a specific CDC42 gene variant.
Did growth hormone help the child in this report?
Yes, the report says the child had favorable catch-up growth after receiving recombinant human growth hormone for six months. However, this is only one case, so the result may not apply to others.
Were there any side effects from the growth hormone?
The case report does not mention any side effects or safety concerns. That does not mean there are none. It only means none were reported in this single case.
Can I get growth hormone for my child with this syndrome?
This report is early evidence and does not prove the treatment works for everyone. Decisions about growth hormone should be made with your child's doctor, who can consider the risks and benefits.
More on Short Stature
View Original Abstract ↓
Evaluating Text Message Video Interventions for Improving Infant Sleep Safety Practices
Text message videos for safe sleep show mixed results
Related in Pediatrics
From Other Specialties
